market share feed enzymes

market share feed enzymes

AB Vista grew its market share in the core enzyme market, increasing revenue growth by 30 per cent in the year ending September 2011. And next year, AB Vista promises an even more exciting development.

Working with its strategic supply and development partners such as AB Enzymes, ROAL and AB Mauri, AB Vista has enjoyed unprecedented demand over the last year for all categories of its feed micro-ingredient products, recording revenue increases across all regions, helping establish what has now become a major feed ingredients platform.

AB Vista's Managing Director, Richard Cooper, said: "I am delighted that AB Vista has made such a major contribution to the growth of AB Agri. AB Vista was able to grow its market share in the highly competitive feed enzyme sector and we are on track to become the 3rd biggest player in 2012. Our ongoing investment in the field of animal nutrition, and the continued focus on the needs of our customers worldwide, have helped us lead by example, and build towards our goal of technical leadership in this sector."

Over the past year, in readiness for further growth, AB Vista has been steadily expanding its team, taking on a total of 18 new employees at its UK headquarters and across its network of international offices. Even more importantly, the company is now gearing up to announce what the company believes will be the most exciting breakthrough in animal nutrition of the last 10 years – at the International Poultry Exhibition (IPE), Atlanta. All will be revealed during IPE Week, which starts on 23 January 2012.

Read More

Enzyme demand in China

Enzyme demand in China

"Supply and Demand of Enzyme in China" report to their extensive offering of biotechnology market research publications.

Up to now, China has been one of the most important enzyme suppliers and consumers in the world, the enzyme industry has been developing fast in the past few years. Although enjoying the strong growth momentum, the Chinese enzyme industry also faces some constraints. The domestic industry is falling behind the global pace, and great disparity exists between China's enzyme industry and overseas counterparts in terms of product structure, production scale, industry standard, etc.

Generally, China's enzyme products are not developed in a sustainable way and the popular products are concentrated among products like a-amylase, glucoamylase and alkaline protease.

CCM International Limited published a market report named Future of Enzyme in China to 2020 in Feb 2010. In order to meet clients' different demands and provide better value products, CCM separated it into many sub-reports with different specific themes. Supply and Demand of Enzyme in China is one of those sub-reports.

Key Topics Covered:

- Enzyme supply in China

- Enzyme Production in China

- Glucoamylase (GA)

- a-amylase

- Protease

- Lipase

- Cellulase

- Non-starch polysaccharides enzymes (NSP enzymes)

- Rennin

- Pectinase

- Xylanase

- Glucanase

- Import and export situation

- Demand of enzyme preparations in China

- Market size of enzyme preparations

- Overall market size

- Market size by enzyme

- Market size by segment

- Consumption pattern of major enzyme preparations

- Introduction to major segments

- And more...

Companies Mentioned:

- Novozymes

- Hunan Jinshi Hongyingxiang Bioengineering Co Ltd

- Zhaodong Sun Shine Enzyme Co Ltd

- Wuxi Syder Bio-products Co Ltd

- Guangzhou Shuangqiao Co Ltd

- Luzhou Food Group Co Ltd

- Nice Group Co Ltd

- Huafang Joint Stock Co Ltd

- Beijing Yanjing Brewery Group Co Ltd

Research and Markets

We are the world's leading source for market research and market data, and we hold over 700,000 major research publications from leading publishers, consultants and analysts worldwide. We can provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. We are a one-stop shop for market research reports and industry newsletters from specialist research firms and niche market analysts, and we have clients in over 100 cities worldwide.

Read More

Extra Feed Enzymes (phytase, Complex Enzyme, Probiotic)

Extra Feed Enzymes (phytase, Complex Enzyme, Probiotic)

1. Phytase

The Phytase added will not only increase the availability of phosphorus and used as an attractive alternative to the inorganic phosphorus such as dicalcium phosphate in feeds, but also is capable to releases other nutrients such as macro-minerals, trace-minerals and amino acids which are also bound to the phytate molecule to give the feed a higher nutritional value, furthermore, as the phosphorus from animal manure can be reduced, this will result in reduce the environment impact and pollution

2. Complex Enzyme

The complex enzyme (Model No. Maxizyme) is especially designed which is used as the anti-nutritional factors (NSP) enzymes in feeds which based on corn-miscellaneous, wheat, rye or other cereals in combination with barley and cereal by-products, by continuous research and study, the Maxizyme is featured with high and stable enzyme activity for animals

Currently, many feed ingredients are not fully digested and absorbed by livestock due to the presence of nonstarch polysaccharides (NSP) which interfere with digestion, but by adding the feed enzymes, the digestibility of the animal can be improved and viscosity of the gut contents can be reduced especially using the NSP enzymes, the main using benefits of that is faster growth of animal, better feed conversion ratio and health status

3. Probiotic

The effective microorganisms (Model No. Bio-EM) is a class of biological agent which commonly recognized as probiotic consisting of living bacteria which feed to animal to improve the desirable microflora balance within the small and large intestine

To be effective, the desirable effective microorganisms will establish as normal inhabitants in the intestinal tract of animals by surviving and flourishing in the gut environments. It is thought to work by either directly excluding harmful bacteria or by reducing intestinal PH to indirectly favor the development of desirable health-promoting microorganisms which compete with harmful bacteria to reduce their presence in the gut.

The desired effect is to improve weight gain and feed efficiency by improving gut digestion and reducing pathogenic organism loads.

Read More

CEVA animal health

CEVA animal health

Ceva Animal Health UK has announced that following the success of it's TV advertising campaign for Feliway earlier this year, which boosted sales by 30%, it'll be running the Feliway campaign again, throughout July.

Featuring 'That Purple Cat', who is liked by over 2,300 people on Facebook, Ceva says the campaign will help raise awareness of the signs of behavioural issues in cats, such as vertical scratching, and highlight the benefits of using the pheromone. The advertisement will target Feliway's key audience and will be seen by over 5 million people when it appears on channels...

Read More

World Enzymes to 2013

World Enzymes to 2013

Global enzyme demand will rise 6.3 percent annually through 2013, driven by strong demand in the specialty enzymes segment and good growth in animal feed and ethanol markets. North America and Western Europe will see healthy market gains while the fastest growth remains in developing countries.

This study analyzes the $5.1 billion world enzyme industry. It presents historical demand data for the years 1998, 2003 and 2008, and forecasts for 2013 and 2018 by product (e.g., carbohydrases, proteases, polymerases and nucleases, lipases), market (e.g., industrial, specialty), world region and for 16 countries.

The study also considers market environment factors, details industry structure, evaluates company market share and profiles 33 industry players, including Novozymes, Danisco and Genzyme.

...Read More

New Probiotic takes industry standard to higher level this year

New Probiotic takes industry standard to higher level this year

Building on the success of CYLACTIN ME10, the industry standard for inclusion in processed and pelleted feed, CYLACTIN ME20 offers even greater stability during the intense processing and pelleting conditions in modern feed production.

Like its predecessor, CYLACTIN ME20 is a live probiotic that produces lactic acid

Dr Christophe Paulus, DSM Global Category Manager Eubiotics, comments: "While CYLACTIN ME10 has long been accepted as the industry standard for top performance, pre-conditioning of feed is taking longer now than in the past, with pelleting occurring at even higher temperatures. This means that increased protection is needed for the probiotic strain. DSM's new CYLACTIN ME20 plus features all the advantages of CYLACTIN ME10 in combination with improved thermostability. This brand new product comes with tougher encapsulation for even better probiotic survival during the increasingly intensive processing and pelleting conditions in modern feed production.

The innovative new coating materials in CYLACTIN ME20 plus allow the proven probiotic strain Enterococcus faecium NICMB 14015 to withstand energy inputs of up to 45kW/t and pelleting temperatures to 95°C – an improvement of 10°C.CYLACTIN ME20 plus is available for broilers, sows, piglets and feeding pigs, and for inclusion in milk replacers.

...Read More

Top news Indonesia| Ceva discusses the epidemiology, vaccine and vaccination of ND

Top news Indonesia| Ceva discusses the epidemiology, vaccine and vaccination of  ND

Epidemiology of Newcastle Disease (ND) was one of the main issues discussed by Dr. Giovanni Cattoli of Istituto Zooprolifattico Sperimentale delle Venezie recently in Bogor, Indonesia. This technical seminar was conducted by PT. Ceva Animal Health Indonesia.

Cattoli explained that ND shares several epidemiological features. That’s why increasing targeted surveillance and biosecurity will determine better prevention and control on both infections.

To do that, Cattoli recommends constant monitoring of the efficacy of laboratory test procedures to guarantee the most adequate diagnostic approach. He also said that data sharing of surveillance data including epidemiological and virological data will allow better vaccine preparedness and the development of tailored control strategies.

Vaccine & Vaccination

Because ND has different epidemiological conditions, Christophe Cazaban – Poultry Biologicals Scientific Direction Officer of Ceva Santé Animale, France said that ND vaccination including vaccine, vaccine administration and vaccination programs are important.

Talking about vaccines, Cazaban said that many ND vaccine strains are available. But its tolerance and strength should be considered in order to choose good quality ND vaccines. He continued, interference between passive immunity (MDA – Maternal Derived Antibody) and classical vaccines is one of the major problems associated with ND vaccination. The fact is that MDA reduce and shorten protection induced by classical live ND vaccines. Besides that, MDA reduce and delay protection induced by classical inactivated ND vaccines.

To overcome the interference problem, Cazaban believes that vector vaccine HVT-NDV could be the promising answer. He said that vector vaccine HVT-NDV induces a stronger immunity, even in the presence of MDA. It also doesn’t spread and creates no lesion of the trachea. “Although it has many advantages, but injection must be perfectly made,” he concluded.

...Read More

Vietnam halts nationwide poultry vaccination for world

Vietnam halts nationwide poultry vaccination for world

The nationwide vaccination of poultry against bird flu in Vietnam has been halted as a new type of the H5N1 virus had rendered the vaccine ineffective the Vietnamese government has said.

The government said in a statement that a new type of the virus had appeared in 2010 following post-vaccination surveillance. Vietnam had planned to use a vaccine imported from China for its vaccination this year, but the vaccine did not work against the new variety, the Animal Health Department said.

The new type has been circulating in northern provinces, coastal provinces in the central region as well as in the Central Highlands, although it was reported that the old type of the virus remains active in southern provinces.

H5N1 virus in poultry was first detected in Vietnam in 2003 and health experts now fear that the disease could mutate to a form that could be easily transmitted between humans. Almost all of the human H5N1 infections to date are believed to have passed from birds to humans.

Vietnam has detected no human cases of bird flu in 2011 but several provinces across the country have reported outbreaks in ducks and chickens.

...Read More

Vaccination as part of an avian influenza control strategy 2011

Vaccination as part of an avian influenza control strategy 2011

In recent times these outbreaks have been occurring with increasing regularity. Outbreaks are typically of a low pathogenic form of avian influenza (LPAI). Past experience indicates that in a susceptible domestic poultry population, circulating LPAI (especially H5- and H7- subtypes) has the ability to mutate into a more devastating high pathogenic avian influenza (HPAI) resulting in Fowl Plague.

Vaccination as an additional control tool has been used with success in controlling LPAI5 outbreaks as well as HPAI outbreaks in the past (1995 - Utah, USA; 2000 - Italy3 & California, USA; 2001 - Hong Kong; 2002 - Colorado, USA). At the Fifty-Second Western Poultry Disease Conference held in Sacramento, California during March 2003 Capua and Marangon2 proposed a scheme, summarised in Diagram 1, whereby vaccination is included in the control strategy in certain scenarios.

The concept of vaccination in the face of HPAI is however met with much resistance based on the arguments that it is not in line with OIE or EU control strategies, would have an negative impact on export trade agreements and potentially masks the symptoms of the disease thus removing the most significant early warning signal for HPAI - acute increase in mortality.

The DIVA strategy is based on the use of an inactivated oil emulsion vaccine containing the same haemagglutinin (H) subtype as the field virus, but a different neuramidase (N). The homologous H group ensures protection while it is possible to differentiate vaccinated from infected birds based on the serological response to the N group using an indirect immunofluorescence test. Vaccinated birds should only test positive to the N group used in the vaccine, a positive reaction to the N group of the prevailing infective virus would indicate a field challenge.

...read more

Poultry sales plummet in Beijing and Shanghai after three bird flu outbreak

Poultry sales plummet in Beijing and Shanghai after three bird flu outbreak

After three bird flu outbreaks hit flocks in different parts of China, sales of poultry in the country's main cities have taken an 80% nosedive. Health experts say that if China cannot prevent future outbreaks of bird flu among its flocks, it is only a question of time before people become infected. According to Chinese authorities, no human in China currently has bird flu.

Even though the price of chicken has dropped 50%, many people are shunning the product and going for other sources of protein.

Health officials say it is not possible to catch bird flu from well cooked chicken or eggs. For a human to catch bird flu he/she needs a lot of contact with live birds. It is possible to catch bird flu if you are involved with the slaughtering of poultry and some of the birds are infected. Bird droppings can also be a source of infection. In some rare cases, humans have caught it from other humans, but only if a person was treating an infected patient and was touching him/her a lot and with him/her for a long time.

For the moment, it is not easy for a human to catch bird flu.

Within the last few weeks there have been three important outbreaks of bird flu among flocks in China. One was in Inner Mongolia (chickens and ducks), another in Anhui and another in Hunan.

...read more

Vietnam halts bird flu vaccination to new type

Vietnam halts bird flu vaccination to new type

(Reuters) - The Vietnamese government said it had halted the nationwide vaccination of poultry against bird flu, saying a new type of the H5N1 virus had rendered the vaccine ineffective.

"Based on post-vaccination surveillance results, a new clade of the H5N1 virus has appeared in Vietnam since 2010," the government said in a statement issued late on Thursday.

Vietnam had planned to use a vaccine imported from China for its vaccination this year, but the vaccine did not work against the new variety, the Animal Health Department said.

The new type has been circulating in northern provinces, coastal provinces in the central region as well as in the Central Highlands, it said.

The old type of the virus remains active in southern provinces, it said in a report this week.

Vietnam has detected no human cases of bird flu in 2011 but several provinces across the country have reported outbreaks in ducks and chicken.

...read more

Venky’s sets up poultry vaccine unit in Switzerland

Venky’s sets up poultry vaccine unit in Switzerland

MUMBAI (Commodity Online):The VH Group (Venkateshwara Hatcheries) has become the first Indian company to set up a state-of-the-art poultry vaccine manufacturing facility in the Canton of Jura in Switzerland.

Working with the economic promotion agency, BaselArea, the VH Group was able to find an appropriate site in Bassecourt, in the Canton of Jura and to establish the new company in Switzerland within the shortest time possible.

The VH Group (Venkateshwara Hatcheries) is the leading Indian poultry conglomerate based in Pune. Incorporated under the name Venky’s Inc., the state of the art manufacturing facility in Bassecourt will provide a major stepping stone for the VH Group to strengthen its position in the European market.

Get a bigger political picture to help you invest

“One of the main reasons for us to come here is the high quality standard related to Switzerland”, said B. Venkateshwara Rao, Managing Director of the VH Group. “Thanks to the uncomplicated and efficient collaboration by all the partners of BaselArea, we were able to quickly find an appropriate site and to establish the company here.”

Provided that the approval process goes according to plan, the new production facility in Bassecourt should become operational by the end of 2011, providing up to 50 job opportunities in the region in the initial year of operation. The VH Group will produce poultry vaccines for the European, Asian and other regulated markets in Bassecourt, Switzerland.

“I am pleased to welcome the VH Group to the Basel area.”, says Dr. Franz A. Saladin, CEO of BaselArea. “The strong life sciences industry here provides an ideal home for this modern facility and we look forward to a continued collaboration with Venky’s.”

Established in 1971, the VH Group (Venkateshwara Hatcheries) is a fully integrated poultry company in India, with a turnover of approx. USD 700 million. It provides complete poultry solutions from basic breeding to providing ready-to-eat chicken and processed egg variants. VH markets its products through the ‘Venky’s’ brand. (IndiaPRWire).

...read more

Merial launches poultry vaccine in china

Merial launches poultry vaccine in china

"Merial’s VAXXITEK HVT + IBD, a high-technology vector vaccine which protects chickens against infectious bursal disease (IBD) and Marek’s disease has been launched in China.

The launch took place in Hangzhou city on 18 April in front of an invited audience of producers and veterinarians. Speaking at the event, Professor BI (Chairman Wen Central Research Institute) said: ‘In terms of IBD control, VAXXITEK HVT + IBD will be magical for China’s poultry industry. As we experienced first hand at Wen with our 700 million color broiler production, VAXXITEK HVT + IBD is convenient to use, controls vaccination better and improves feed conversion.'

VAXXITEK HVT + IBD is registered in 66 countries around the world. First was Brazil where over 5 billion birds have been vaccinated since launch in 2006. Addressing the audience in Hangzhou, Dr Fabricio Delgado of Brazil Foods said: 'We have used VAXXITEK HVT + IBD for four years. It improves performance, especially feed conversion and delivers a great return on investment for our business. As a hatchery vaccine, VAXXITEK HVT + IBD is also beneficial for biosecurity.'

VAXXITEK HVT + IBD ...read more

Ceva opens new poultry vaccine production facility

Ceva opens new poultry vaccine production facility

Ceva Animal Health is pleased to announce the May 3, 2011 opening of a new poultry vaccine production facility at its Biomune Campus in Lenexa, Kansas.

“After many years of building a strong research and development base, along with a fine sales force and excellent technical support, we are investing in our future growth with the opening of this new production facility,” said Dr. Arnaud Bourgeois, Vice President and Global Director of Biology at Ceva Santé Animale. “Increased demand for Ceva vaccines, plus the ability to create and utilize new vaccine technology not available from competitors made this the perfect time to build our new facility.”

Ceva Santé Animale purchased Lenexa-based Biomune Company in 2005, creating Ceva Animal Health as its US subsidiary. The purchase secured a strong foundation in research with Vectormune vaccines along with an aging manufacturing plant. With the opening of its new $18M facility, Ceva is poised to fill a global market need with high-quality vaccines. “Today, what we output is almost entirely for the domestic market,” explains Bourgeois, “ The new facility will double our domestic output while also allowing for expansion globally.” The existing plant will be renovated as part of Ceva’s long-term investment plan and is designated for a stand-alone custom vaccine project.

Ceva is well-known for its dedication to providing animal health products and services that ultimately benefit humans. The Biomune Campus’s contribution to the “One Health” effort is clear: poultry vaccines keep the world’s food supply safe and sufficient to meet the needs of an ever-growing population. “We continue to invest in our people and our facilities in order to innovate and therefore ensure that our products and services have a direct impact in improving global health,” said Marc Prikazsky, Chief Executive Officer of Ceva Santé Animale.

...read more

The Chicken Health Connection

The Chicken Health Connection

Taiwan, one of few East Asian countries to have avoided H5N1, is enjoying bumper exports of frozen ducks. Some importers chose frozen ducks from Taiwan and found they were superior for their needs and cheaper than ducks from elsewhere. On September 9, 2008, Central News Agency (Taiwan), using figures from Council of Agriculture (COA), said Taiwan maintained its traditional frozen duck export markets and opened new ones in 2007.

Taiwan raised 11 million ducks in 2007 with a production value of around US$193 million and fgained export revenues of US$26 million. Central News Agency interviewed Lin Chih-yuan, deputy manager of the Ger Chuan Foods Inc., a leading duck meat exporter, who said, “Even Japan, which has high hygiene standards for imported meat, welcomes Taiwan duck meat. In 2007, Taiwan sold 5,000 tons of duck meat to Japan to make Beijing duck,” Lin Chih-yuan said. Taiwan also succeeded in penetrating the South Korean market during 2007 and exported 700 tonnes of frozen whole ducks or duck meat for the year.

...read more

New Vaccine Developed Newcastle Disease against

New Vaccine Developed Newcastle Disease against

US - A new vaccine against Newcastle disease (ND) in poultry has been developed by US Department of Agriculture (USDA) scientists in Athens, Georgia.

USDA ARS

USDA

Using reverse genetics technology, the new vaccine is made from part of a virus that is similar to the wild-type Newcastle disease virus (NDV) circulating in the environment today.

Agricultural Research Service (ARS) scientists in the agency's Southeast Poultry Research Laboratory in Athens developed the vaccine, which not only reduces mortality and severity of NDV symptoms in poultry, but also decreases the amount of virus spread as well. ARS is USDA's principal intramural scientific research agency, and the research supports the USDA priority of promoting international food security.

Led by microbiologist Qingzhong Yu, the researchers found that reverse genetics technology enabled them to generate a new vaccine by exchanging a gene from the original vaccine with a similar gene of the current circulating virus. When the new vaccine, containing gene sequences similar to the wild-type virus, was used in vaccination studies, the vaccinated birds were protected from disease and shed less of the wild-type virus after infection.

Current vaccines for Newcastle disease are used widely in commercial poultry and protect the vaccinated birds from disease, but do not stop the virus from being spread from infected to healthy birds. A vaccine that reduces both the shedding of the virus and spreading of viruses among birds is sorely needed by the industry, according to Dr Yu.

Most vaccines used in the United States are formulated with NDV isolated in the 1940s. However, since then new NDV strains have emerged that are genetically different, said Dr Yu.

NDV causes disease in more than 250 species of birds and typically causes respiratory, gastrointestinal and/or nervous system symptoms. The most severe form of Newcastle disease can result in disease and mortality rates exceeding 90 percent in susceptible chickens. The most recent US outbreak, which occurred in 2002-2003 in California, Nevada and Texas, illustrates the devastation and financial cost that can result: more than 3.4 million birds were destroyed, and the cost of controlling the outbreak in California alone was more than $160 million.